Treatment of axillary hyperhidrosis with botulinum toxin type A reconstituted in lidocaine or in normal saline: a randomized, side-by-side, double-blind study
- PMID: 17286630
- DOI: 10.1111/j.1365-2133.2007.07760.x
Treatment of axillary hyperhidrosis with botulinum toxin type A reconstituted in lidocaine or in normal saline: a randomized, side-by-side, double-blind study
Abstract
Background: Botulinum toxin type A represents a safe and effective treatment for primary axillary hyperhidrosis. One of the most troublesome disadvantages associated with this therapy is pain at the injection sites. Reconstitution of botulinum toxin A in a solution of lidocaine could be an easy alternative procedure to reduce the discomfort associated with those injections. However, the current recommendations are that botulinum toxin A should be reconstituted in normal saline.
Objectives: To compare the efficacy and tolerance profile of saline-diluted botulinum toxin A and lidocaine-diluted botulinum toxin A in patients with axillary hyperhidrosis.
Methods: In a double-blind, side-by-side, controlled, randomized clinical trial, 29 patients were injected with 100 mouse units of botulinum toxin A (Botox); Allergan Pharmaceuticals Ireland, Westport, Ireland) reconstituted in lidocaine into one axilla and with the same dosage of the toxin, reconstituted in an equal volume of saline, into the other axilla. The patients were followed up for 8 months. Quantification of sweat production was performed by iodine-starch tests and by the patients' own rating of sweating. The intensity of pain associated with the botulinum toxin intracutaneous injections was self-assessed by the patients and was evaluated using a 100-mm visual analogue scale.
Results: Botulinum toxin A diluted in normal saline and botulinum toxin A diluted in lidocaine were similarly effective in terms of control of onset of sweat production, duration of effect and subjective percentage of mean decrease in sweating. Both treatments were well tolerated, and there were no lasting or severe adverse effects. However, the mean +/- SD pain score during the procedure was significantly lower in the axillae treated with lidocaine-reconstituted botulinum toxin than in the axillae treated with saline-reconstituted botulinum toxin (29.3 +/- 20.1 vs. 47.5 +/- 24.0; P = 0.0027).
Conclusions: Short- and long-term results show the equal effectiveness of botulinum toxin A reconstituted in saline or in lidocaine. However, because injections of botulinum toxin A reconstituted in lidocaine are associated with significantly reduced pain, lidocaine-reconstituted botulinum toxin A may be preferable for treating axillary hyperhidrosis.
Similar articles
-
Dilution of botulinum toxin A in lidocaine vs. in normal saline for the treatment of primary axillary hyperhidrosis: a double-blind, randomized, comparative preliminary study.J Eur Acad Dermatol Venereol. 2012 Mar;26(3):314-8. doi: 10.1111/j.1468-3083.2011.04066.x. Epub 2011 Apr 15. J Eur Acad Dermatol Venereol. 2012. PMID: 21492253 Clinical Trial.
-
Low-dose efficacy of botulinum toxin A for axillary hyperhidrosis: a randomized, side-by-side, open-label study.Arch Dermatol. 2005 Oct;141(10):1255-9. doi: 10.1001/archderm.141.10.1255. Arch Dermatol. 2005. PMID: 16230563 Clinical Trial.
-
Botulinum toxin A for axillary hyperhidrosis (excessive sweating).N Engl J Med. 2001 Feb 15;344(7):488-93. doi: 10.1056/NEJM200102153440704. N Engl J Med. 2001. PMID: 11172190 Clinical Trial.
-
Axillary injection of botulinum A toxin in a patient with muscle cramps associated with severe axillary hyperhidrosis.Acta Neurol Belg. 2001 Jun;101(2):121-3. Acta Neurol Belg. 2001. PMID: 11486559 Review.
-
Treatment of axillary hyperhidrosis by chemodenervation of sweat glands using botulinum toxin type A.J Drugs Dermatol. 2004 Nov-Dec;3(6):627-31. J Drugs Dermatol. 2004. PMID: 15624745 Review.
Cited by
-
Lacrimal gland botulinum toxin injection for epiphora management.Orbit. 2022 Apr;41(2):150-161. doi: 10.1080/01676830.2021.1966810. Epub 2021 Aug 15. Orbit. 2022. PMID: 34396904 Free PMC article. Review.
-
Anatomical consideration for botulinum toxin injection of the frontalis muscle based on analysis of intramuscular innervation.Sci Rep. 2025 Mar 14;15(1):8919. doi: 10.1038/s41598-025-93900-x. Sci Rep. 2025. PMID: 40087484 Free PMC article.
-
Current and Emerging Medical Therapies for Primary Hyperhidrosis.Dermatol Ther (Heidelb). 2017 Mar;7(1):25-36. doi: 10.1007/s13555-016-0148-z. Epub 2016 Oct 27. Dermatol Ther (Heidelb). 2017. PMID: 27787745 Free PMC article. Review.
-
[Botulinum toxin in focal hyperhidrosis. An update].Hautarzt. 2012 Jun;63(6):469-76. doi: 10.1007/s00105-012-2333-z. Hautarzt. 2012. PMID: 22638981 Review. German.
-
Injection Site Pain, Onset and Duration of Action of Botulinum Toxin Reconstituted in Normal Saline With and Without Sodium Bicarbonate: A Prospective, Single Center, Randomized, Double-Blind Interventional Study.Plast Surg (Oakv). 2022 Aug;30(3):227-232. doi: 10.1177/22925503211011971. Epub 2021 May 12. Plast Surg (Oakv). 2022. PMID: 35990391 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical